Baird transferred coverage and downgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Outperform to Neutral with a price target of $133.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE